{"id":"NCT00618748","sponsor":"Eli Lilly and Company","briefTitle":"Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed","officialTitle":"Safety and Efficacy of Olanzapine (LY170053) in the Long-term Treatment for Patients With Bipolar I Disorder, Depressed","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2008-02-20","resultsPosted":"2011-06-27","lastUpdate":"2011-07-27"},"enrollment":101,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar I Disorder"],"interventions":[{"type":"DRUG","name":"Olanzapine","otherNames":["LY170053"]}],"arms":[{"label":"Pre-Olanzapine","type":"EXPERIMENTAL"},{"label":"Pre-Placebo","type":"EXPERIMENTAL"},{"label":"New Olanzapine","type":"EXPERIMENTAL"}],"summary":"To assess the efficacy and safety of olanzapine in the long-term treatment for patients with bipolar I disorder, depressed.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events Leading to Discontinuation","timeFrame":"Baseline through 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)","effectByArm":[{"arm":"Pre-Olanzapine","deltaMin":7.1,"sd":null},{"arm":"Pre-Placebo","deltaMin":12,"sd":null},{"arm":"New Olanzapine","deltaMin":40,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["Japan"]},"refs":{"pmids":["24417745"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":56},"commonTop":["Weight increased","Nasopharyngitis","Increased appetite","Headache","Somnolence"]}}